{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:11:36Z","timestamp":1790143896713,"version":"4.0.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tegoprazan is a newer P-CAB with favorable tolerability, yet data on hepatic safety remain limited. We compared the incidence of laboratory-defined hepatic events between tegoprazan and esomeprazole, a PPI with a well-established safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective new-user cohort study at a tertiary hospital in Korea. Adults prescribed tegoprazan or esomeprazole for \u226514 days between March 2019 and December 2024 were included. A laboratory-defined hepatic event was defined as \u22651.5-fold elevation from baseline in ALT, bilirubin, or GGT above the upper limit of normal within 120 days. Propensity score matching was applied, and risks were compared using Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, 2,970 tegoprazan and 4,634 esomeprazole users were analyzed. Tegoprazan was associated with fewer laboratory-defined hepatic events (adjusted HR 0.73, 95% CI 0.56\u20130.95). The association was consistent in sensitivity analyses and was also observed in patients with baseline ALT below the upper limit of normal (aHR 0.70, 95% CI 0.53\u20130.93). Follow-up ALT elevations &amp;gt;100 U\/L were less frequent with tegoprazan than esomeprazole (0.8% vs. 2.0%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tegoprazan was associated with fewer laboratory-defined hepatic events than esomeprazole in this dataset. These findings are hypothesis-generating and require confirmation using standardized monitoring and adjudicated outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1872116","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:49:25Z","timestamp":1790142565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative hepatic safety between tegoprazan and esomeprazole: a real-world cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ji Eun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwon","family":"Kim","sequence":"additional","affiliation":[{"name":"Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Kang","sequence":"additional","affiliation":[{"name":"Health Promotion Center, Samsung Medical Center, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]},{"name":"Digital Innovation Center, Samsung Medical Center, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]},{"name":"Department of Digital Health, SAIHST, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunga","family":"Kim","sequence":"additional","affiliation":[{"name":"Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center","place":["Seoul, Republic of Korea"]},{"name":"Department of Digital Health, SAIHST, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]},{"name":"Department of Data Convergence and Future Medicine, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Sinn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poong Lyul","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/apt.15865","article-title":"Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer","volume":"52","author":"Cho","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e080409","DOI":"10.1136\/bmj-2024-080409","article-title":"Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study","volume":"387","author":"Feldman","year":"2024","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5009\/gnl220050","article-title":"Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study","volume":"17","author":"Han","year":"2023","journal-title":"Gut Liver"},{"key":"B6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12876-023-02772-w","article-title":"Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis","volume":"23","author":"Haruma","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","article-title":"Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases","volume":"168","author":"Inatomi","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1076356","DOI":"10.3389\/fmed.2022.1076356","article-title":"Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: a nationwide cohort study","volume":"9","author":"Kim","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.cgh.2024.05.004","article-title":"Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial","volume":"22","author":"Laine","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3164\/jcbn.11-94","article-title":"Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating akt signaling","volume":"51","author":"Lee","year":"2012","journal-title":"J. Clin. Biochem. Nutr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/apt.15185","article-title":"Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis","volume":"49","author":"Lee","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"27173","DOI":"10.1038\/s41598-024-78581-2","article-title":"Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy","volume":"14","author":"Lee","year":"2024","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/CEG.S228352","article-title":"Vonoprazan fumarate for the treatment of gastric ulcers: a short review on emerging data","volume":"13","author":"Marabotto","year":"2020","journal-title":"Clin. Exp. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e076268","DOI":"10.1136\/bmj-2023-076268","article-title":"Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study","volume":"385","author":"Mok","year":"2024","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/apt.16121","article-title":"Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects","volume":"52","author":"Sunwoo","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/liv.14713","article-title":"Incidence and prevalence of acute hepatitis E virus infection in patients with suspected drug-induced liver injury in the Spanish DILI registry","volume":"41","author":"Sanabria-Cabrera","year":"2021","journal-title":"Liver Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium-competitive acid blockers: current clinical use and future developments","volume":"26","author":"Scarpignato","year":"2024","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/joim.12826","article-title":"Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study","volume":"285","author":"Tran-Duy","year":"2019","journal-title":"J. Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s11096-016-0299-0","article-title":"Methods to control for unmeasured confounding in pharmacoepidemiology: an overview","volume":"38","author":"Uddin","year":"2016","journal-title":"Int. J. Clin. Pharm."},{"key":"B23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/liv.14306","article-title":"Clinicopathological features of Bu Gu Zhi-induced liver injury, a long-term follow-up cohort study","volume":"40","author":"Wang","year":"2020","journal-title":"Liver Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e00776","DOI":"10.14309\/ctg.0000000000000776","article-title":"Network meta-analysis of comparing different dosages of potassium-competitive acid blocker with proton-pump inhibitor in acid-related disorders","volume":"15","author":"Wang","year":"2024","journal-title":"Clin. Transl. Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/clpt.2014.129","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1111\/bcp.15268","article-title":"Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole","volume":"88","author":"Yang","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e18636","DOI":"10.7717\/peerj.18636","article-title":"CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms","volume":"12","author":"Zhang","year":"2024","journal-title":"PeerJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/phar.2899","article-title":"Acid-suppressive drugs: a systematic review and network meta-analysis of their nocturnal acid-inhibitory effect","volume":"44","author":"Zou","year":"2024","journal-title":"Pharmacotherapy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1872116\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:49:26Z","timestamp":1790142566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1872116\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":28,"alternative-id":["10.3389\/fphar.2026.1872116"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1872116","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1872116"}}